Listen to this article
Estimated 4 minutes
The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results.
Two cases of the deadly Nipah virus in India have prompted authorities in Thailand and Malaysia to step up airport screening to prevent the spread of the infection.
But what is Nipah virus, and how worried should people be? Here are some answers.
India’s Health Ministry said Tuesday that two Nipah cases had been detected since December and that all identified contacts had been quarantined and tested. The ministry did not release details about the patients, but said 196 contacts had been traced and all tested negative.
“The situation is under constant monitoring, and all necessary public health measures are in place,” the ministry said.
There were no reported cases of the virus outside India, but several Asian countries introduced or reinforced screening measures at airports as a precaution.
What is Nipah virus?
Nipah is a rare viral infection that spreads largely from infected animals, mainly fruit bats, to humans. It can be asymptomatic but it is often very dangerous, with a case fatality rate of 40 to 75 per cent, depending on the local health-care system’s capacity for detection and management, the World Health Organization says.
However, while it can also spread from person to person, it does not do this easily, and outbreaks are usually small and fairly contained, according to experts and the European Centre for Disease Prevention and Control. Candidate vaccines are under development, although none have been approved yet.
How common is it?
Nipah was first identified in Malaysia in 1999. Since then, there have been small outbreaks almost every year, mostly in Bangladesh. India also sees sporadic outbreaks.
According to the Coalition for Epidemic Preparedness Innovations, a group that tracks emerging disease threats and funds the development of medical tools to protect against them, as of December, 750 cases had been recorded in all, and 415 of the patients died.
How does it spread?
When first identified in Malaysia, Nipah spread largely through direct contact with sick pigs or contaminated tissues. Since then, it more commonly spreads from contact with what scientists say is its natural host: fruit bats.
More specifically, the consumption of fruit or fruit products — like raw date palm juice — containing urine or saliva from infected fruit bats has been the most likely source of infection, the WHO says. Human-to-human spread has been found, mainly after close contact between a sick patient and their family or caregivers.
What are the symptoms?
The initial symptoms of Nipah, such as fever, headaches and muscle pain, are not specific and can be confused with other diseases. These can then be followed by neurological signs indicating acute encephalitis, or inflammation of the brain, and some people experience severe respiratory problems.
Ten people there have died after being infected with the Nipah virus, a disease thought to be spread by fruit bats and other animals.
Seizures occur in severe cases, progressing to a coma in days. Most people who get better make a full recovery, but some experience long-term neurological problems.
How worried should we be?
While Nipah is a dangerous disease with a high fatality rate, it has not yet shown signs of becoming more transmissible among humans or spreading easily worldwide, scientists say.
However, it remains a significant public health concern, according to the WHO, particularly in countries where outbreaks are more common. It can also lead to the mass culling of farm animals, such as pigs, that are susceptible to the virus.
Scientists say it is unlikely to spread globally — but also point out that airport screening may be ineffective as the virus has a long incubation period.
What vaccines or treatments are there?
There are currently no approved vaccines or treatments for Nipah, although a number of candidates are undergoing testing, including one developed by the Oxford University scientists involved in developing one of the COVID-19 vaccines.
Their Nipah vaccine uses the same technology, and began Phase 2 testing in Bangladesh in December in collaboration with the International Centre for Diarrhoeal Disease Research, Bangladesh, and with funding from the Coalition for Emergency Preparedness Innovations.
